Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design.

Vaccine·2026
Same author

Impact of <i>Bifidobacterium infantis</i> supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan.

Frontiers in nutrition·2026
Same author

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.

Vaccine·2026
Same author

BCG Revaccination to Prevent Tuberculosis. Reply.

The New England journal of medicine·2025
Same author

Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01<sub>E-4</sub> in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial.

The lancet. HIV·2025
Same author

BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> Infection.

The New England journal of medicine·2025
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Progress in respiratory virus vaccine development.

Alexander C Schmidt1

  • 1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 10001, USA. schmidta@niaid.nih.gov

Seminars in Respiratory and Critical Care Medicine
|August 23, 2011
PubMed
Summary
This summary is machine-generated.

New vaccines are being developed for serious respiratory viruses like respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), and metapneumovirus (MPV). These investigational vaccines aim to reduce illness and death in vulnerable populations.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Influenza A Virus Studies in a Mouse Model of Infection
10:44

Influenza A Virus Studies in a Mouse Model of Infection

Published on: September 7, 2017

Related Experiment Videos

Last Updated: May 30, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Influenza A Virus Studies in a Mouse Model of Infection
10:44

Influenza A Virus Studies in a Mouse Model of Infection

Published on: September 7, 2017

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Viral respiratory infections lead to significant illness and death in infants, young children, and the elderly.
  • While influenza vaccines exist, vaccines for other critical viruses like RSV, PIVs, and MPV are lacking.
  • Focus is on pathogens causing severe lower respiratory illness (LRI).

Purpose of the Study:

  • To review the current status of investigational vaccines against RSV, PIVs, and MPV.
  • To provide an update on vaccines that have undergone clinical trials or are in development.

Main Methods:

  • Literature review of clinical trial data and ongoing vaccine development.
  • Analysis of vaccine candidates targeting RSV, PIVs, and MPV.

Main Results:

  • Several vaccine candidates against RSV, PIVs, and MPV are in various stages of clinical development.
  • Influenza virus vaccines are established, but vaccines for other common respiratory viruses are still under investigation.

Conclusions:

  • Vaccine development for RSV, PIVs, and MPV is progressing.
  • Further research and clinical trials are needed to bring these vaccines to fruition.
  • These investigational vaccines hold promise for reducing the burden of viral respiratory infections.